Our goal has always been to use exceptional science to deliver transformative medicines with a focus on patients.
Kestrel is a clinical-stage biotechnology company focused on developing medicines for patients with intractable cancers driven by KRAS mutations.
Our goal has always been to use exceptional science to deliver transformative medicines with a focus on patients.
Mutations in the RAS family of genes (KRAS, HRAS and NRAS) are present in over 30% of all cancer. Activating mutations of the KRAS isoform, specifically, are observed in more than 20% of all cancers, making it one of the most frequently altered oncogenes. Kestrel’s goal is to develop best-in-class small molecule inhibitors that potently and selectively target KRAS regardless of the mutation or tumor type.
KST-6051 is a potential best-in-class, oral pan-KRAS inhibitor that has been shown in pre-clinical testing to be effective against human tumors and well tolerated. Based on these findings, we are initiating a Phase 1 study in patients with advanced cancers.